Topamax, Topiramate News

Vivus Inc. , maker of experimental weight-loss pill Qnexa, jumped the most in 13 months after U.S. regulators ordered changes to a proposed warning label that may mean more women would be able to take the drug.

Vivus Inc said U.S. health regulators asked the company to remove a contraindication in the proposed label of its obesity drug Qnexa, a move that could help it reach a broader patient population.

Vivus Inc said the U.S. health regulator asked the company to remove a contraindication of its obesity drug in the proposed label that could help the drug reach a broader patient population.

Main Category: Epilepsy Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 01 Jan 2012 - 1:00 PST Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures , reported positive ... (more)

BRANFORD, Conn., Dec. 21, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures , reported positive data in the open-label extension follow up to the company's Phase 2 clinical trial.